CCXIEUR
CHEMOCENTRYX INC
A biopharmaceutical company that developed pill-based medicines for autoimmune and inflammatory diseases, its flagship product being Tavneos (avacopan), an oral treatment for ANCA-associated vasculitis, a rare disease that inflames and destroys small blood vessels. Founded in 1997 by scientist Thomas Schall, the company's name blends "chemo" (for chemokines, the signaling proteins that guide immune cells) with "centryx," a play on "center," reflecting its focus on those pathways. Amgen acquired the company in 2022.
CUSIP: 16383L1061 holder
Recent Activity
2013Q2
1 sell
-162 shares
-162 shares
2013Q1
1 buy
+162 shares
+162 shares